NCT05160389 is a Phase 1 clinical trial of PBI-200 in Food Effect in Healthy Volunteers, sponsored by Pyramid Biosciences.

Who is sponsoring NCT05160389?

NCT05160389 is sponsored by Pyramid Biosciences.

What drugs are being tested in NCT05160389?

Interventions in NCT05160389: PBI-200.

What condition does NCT05160389 study?

NCT05160389 studies Food Effect in Healthy Volunteers.

Is NCT05160389 still recruiting?

NCT05160389 is currently completed. Last updated 27 January 2022.

Last reviewed 2022-01-27 · How we verify

NCT05160389

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Assess the Effect of Food on the Absorption and Bioavailability of PBI-200

Completed Phase 1 Last updated 27 January 2022

What this trial tests

Phase 1 trial testing PBI-200 in Food Effect in Healthy Volunteers in 16 participants. Completed in 6 January 2022.

Timeline

17 November 2021

Primary endpoint
6 January 2022

6 January 2022

Quick facts

Lead sponsor	Pyramid Biosciences
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	16
Start date	17 November 2021
Primary completion	6 January 2022
Estimated completion	6 January 2022
Sites	1 location across United States

Drugs / interventions tested

PBI-200

Conditions studied

Food Effect in Healthy Volunteers — all drugs for Food Effect in Healthy Volunteers →

Sponsor

Pyramid Biosciences — full company profile →

Who can join

Adults 18 to 55, any sex, with Food Effect in Healthy Volunteers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-dose, open-label, randomized, three-way crossover study to assess the effect of food on the absorption and bioavailability of PBI-200.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of PBI-200

Trials testing the same drug.

NCT04901806 — Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors · Phase 1 · terminated

Other recruiting trials for Food Effect in Healthy Volunteers

Currently open trials in the same condition.

NCT07060209 — Food Effect on PK of DW-1021 (Pelubiprofen 45 mg / Tramadol 45.9 mg) in Healthy Adults · Phase 1 · recruiting

Other Pyramid Biosciences trials

Trials by the same sponsor.

NCT05692570 — A Study of PBI-200 With Ritonavir or Cobicistat in Healthy Volunteers · Phase 1 · completed
NCT05690932 — A Formulation Bridging and Food Effect Study of PBI-200 in Healthy Volunteers · Phase 1 · completed
NCT05238337 — A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200 · Phase 1 · completed
NCT05514353 — A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream · Phase 1 · completed
NCT04901806 — Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors · Phase 1 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05160389 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pyramid Biosciences
Last refreshed: 27 January 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05160389.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing